NCT02047903View on ClinicalTrials.gov

GIOTRIF in First Line Therapy of Advanced NSCLC With EGFR-mutations

CompletedOBSERVATIONAL
Enrollment

161

Participants

Timeline

Start Date

March 5, 2014

Primary Completion Date

December 31, 2018

Study Completion Date

December 31, 2018

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG

Afatinib

50, 40, 30 or 20 mg

Trial Locations (1)

Unknown

Multiple Locations

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY